The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite

Drug Metabolism and Disposition

Volumn 26, Issue 8, 1998, Pages 802-811

  Fischer, Volker ^a   Rodríguez Gascón, Alicia ^b   Heitz, Francis ^b   Tynes, Ronald ^b   Hauck, Christian ^b   Cohen, Dalia ^b   Vickers, Alison E M ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANTIPYRETIC ANALGESIC AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; CHLORPROPAMIDE; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DOXORUBICIN; ERYTHROMYCIN; ETOPOSIDE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; MUSCLE RELAXANT AGENT; NIFEDIPINE; OXYTOCIC AGENT; PACLITAXEL; PHENACETIN; PHENAZONE; STEROID; VALSPODAR; VINBLASTINE;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHO CELLS; CRICETINAE; CYCLOSPORINS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; HYDROXYLATION; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN;

CRICETINAE; CRICETULUS GRISEUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0345084436     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV and Gonzalez FJ (1989) Cytochrome P-450 HPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395.
2. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itho Y, Combates NJ, Bair KW and Cohen D (1995) Analysis of the interactions of SDZ PSC 833 ([[3′-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7:603-610.
3. Bachur NR and Gee M (1976) Microsomal reductive glycosidase. J Pharmacol Exp Ther 197:681-686.
4. Ball SE, Maurer G, Zollinger M, Ladona M and Vickers AEM (1992) Characterization of the cytochrome P-450 gene family responsible for N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metab Dispos 20:56-63.
5. Bartlett N, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J and Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842.
6. Bitsch F, Ma W, Macdonald F, Nieder M and Shackleton CHL (1993) Analysis of taxol and related diterpenoids from cell cultures by liquid chromatography-electrospray mass spectrometry. J Chromatogr 615:273-280.
7. Boesch D, Gaverieaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P and Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233.
8. Böhme M, Buchler M, Muller M and Keppler D (1993) Differential inhibition by cyclosporins of primary active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193-196.
9. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH and Blcehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618.
10. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
11. Campana C, Regazzi MB, Buggia I and Molinaro M (1996) Clinically significant interactions with cyclosporin. Clin Pharmacokinet 30:141-179.
12. Colombo T, Zucchetti M and D'Incalci M (1994) Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269:22-26.
13. Coppack W, Lant AF, McIntosh CS and Rodgers AV (1990) Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin-dependent diabetes mellitus. Br J Clin Pharmacol 29:673-684.
14. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I and Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392.
15. 1 activity. Clin Pharmacol Ther 45:34-40.
16. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR and Tarbit MH (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225-1230.
17. Erlichman C, Moore J, Thiessen J, DeAngelis C, Goodman P and Manzo J (1993) A phase I trial of doxorubicin (D) and PSC 833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:134.
18. Fischer V, Vickers AEM, Heitz F, Mahadevan S, Baldeck JP, Minery P and Tynes R (1994) The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22:269-274.
19. Fisher GA, Bartlett NL, Lum BL, Brophy NA, Duran GE, Ehsan MN, Halsey J and Sikic BI (1994) Phase trial of taxol (T) with high dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:144.
20. Fisher GA and Sikic BI (1995) Clinical studies with modulators of multidrug resistance. Drug Resist Clin Oncol Haematol 9:363-382.
21. Fleishaker JC and Phillips JP (1991) Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. J Clin Pharmacol 31:259-262.
22. Gonzalez FJ, Balthazar JS, Umeno M, McBride OW, Hardwick JP, Meyer UA, Gelboin HV and Idle JR (1988a) Human P450PCN1: sequence, chromosomal localization and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7:79-86.
23. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Tanger UM, Nebert DW, Gelboin NV, Hardwick JP and Meyer UA (1988b) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond) 331:442-446.
24. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV and Collins JM (1994a) Isolation, structural determination, and biological activity of 6α-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 37:706-709.
25. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM (1994b) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and unknown P450 enzyme. Cancer Res 54:4026-4035.
26. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113.
27. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P and Hiestand PC (1992) PSC, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug-resistance of murine leukemia. Int J Cancer 50:593-597.
28. Kronbach T, Fischer V and Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630-635.
29. Kumar GN, Walle UK and Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxoi 6α-hydroxylation. J Pharmacol Exp Ther 268:1160-1165.
30. Lehnert M, Emerson S, Dalton WS, de Giuli R and Salmon SE (1993) In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated taxol resistance. J Natl Cancer Inst 15:63-67.
31. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halset J, Gosland MP and Sikic B (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642.
32. Mangold JB, Schran HF and Tse FLS (1994) Pharmacokinetics and metabolism of cyclosporin G in humans. Drug Metab Dispos 22:873-879.
33. Maurer G (1985) Metabolism of cyclosporine. Transplant Proc 17(suppl):19-26.
34. Meyer FP (1994) Indicative therapeutic and toxic drug concentrations in plasma: a tabulation. Int J Clin Pharmacol Ther 32:71-81.
35. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolf A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766.
36. Monsarrat B, Alvinerie P, Wright M, Dubois J, Guéritte-Voegelien F, Guénard D, Donehower RC and Rowinsky EK (1993) Hepatic metabolism and biliary excretion of taxol in rats and humans. Natl Cancer Inst Monogr 15:39-46.
37. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T and Malerio D (1990) Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin A. Int J Cancer 45:263-268.
38. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
39. Pastan IA and Gottesman MM (1988) Molecular biology of multidrug resistance in human cells, in Important Advances in Oncology (De Vita VT, Hellman S and Rosenberg SA eds) pp 3-16, Lippincott, Philadelphia.
40. Pastan I and Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42:277-286.
41. Pichard L, Domergue J, Fourtanier G, Koch P, Schran HF and Maurel P (1996) Metabolism of the new immunosuppressor cyclosporin G by human liver cytochrome P450. Biochem Pharmacol 51:591-598.
42. Pichard L, Fabre I, Fahre G, Domergue J, St Aubert B, Mourad G and Maurel P (1990) Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
43. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW (1994) Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
44. Relling MV, Evans R, Dass C, Desiderio DM and Nemec J (1992) Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 26:491-496.
45. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ and Korzekwa KR (1994) 0-Demethylation of epipodophyllotoxins is catalyzed by the human cytochrome P450 3A4. Mol Pharmacol 45:352-358.
46. Riggs CE, Benjamin RS, Serpick AA and Bachur NR (1977) Biliary disposition of Adriamycin. Clin Pharmacol Ther 22:234-241.
47. 14C an Menschen. Arzneim Forsch 19:1428-1434.
48. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, pp 161-226, John Wiley & Sons, New York.
49. Sonneveld P and Nooter K (1990) Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 75:208-211.
50. Sonneveld P, Schoester M and de Leeuw K (1994) Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 12:1584-1591.
51. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A and Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566-575.
52. Speeg KV and Maldonado AL (1994) Effect of the nonimmunosuppressive cyclosporine analog SDZ PSC on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 34:133-136.
53. Takanashi S and Bachur NR (1976) Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab Dispos 4:79-87.
54. Te Boekhorst PA, van Kapel J, Schoester M and Sonneveld P (1992) Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the MDR1 phenotype. Cancer Chemother Pharmacol 30:238-242.
55. Twentyman PR and Blechen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer 27:1639-1642.
56. Vickers AEM, Meyer E, Dannecker R, Keller B, Tynes R and Maurer G (1995) Human liver CYP3A biotransformation of the cyclosporin derivative SDZ IMM-125. Drug Metab Dispos 23:321-326.
57. Walle T, Walle UK, Kumar GN and Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512.
58. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 46:568-577.
59. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P and Rahmani R (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindisine biotransformation: metabolic drug interactions. Biochem Pharmacol 45:853-861.
60. Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y and Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53:5121-5126.